Navigation Links
OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
Date:11/16/2011

SAN DIEGO, Nov. 16, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, today announced it has entered into a collaborative research agreement with Serametrix Corporation to analyze subjects in three OncoSec Phase II clinical trials treating melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma with the goal of identifying biomarkers that may refine and enhance the selection of patients potentially responsive to these treatments. Terms of the final agreement have not been released.

(Photo: http://photos.prnewswire.com/prnh/20111116/LA07868)

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The advancement of biomarkers able to display the presence of or change in a biological response such as a protein related to a specific disease has been invaluable in improving patient outcomes in the multi-billion-dollar commercial success of multiple medical therapies. Unfortunately, the discovery of biomarkers in the field of cancer immunotherapy has been elusive. Serametrix has been leading the field in developing validated tests to identify such biomarkers, providing simple and robust methods that deliver accurate and reliable results. Using Serametrix's proprietary Seromic™ Profiling Assay, samples of blood taken from patients in OncoSec's three clinical studies will be analyzed with the goal of detecting potential predictive biomarkers and provide an understanding of the broad humoral (antibody) anti-tumor response resulting from OncoSec's immune therapy using DNA IL-12 and electroporation. Identification of a new biomarker(s) may enable the optimal selection of patients most likely to respond to OncoSec's

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. OncoSec Medical Closes $1.1M Financing
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
7. OncoSec Medical Appoints Engineering Leader
8. OncoSec Medical to Present at Industry and Investor Conferences
9. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
10. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
11. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... LOS ANGELES , May 24, 2013  An ... gathered on Saturday, May 18, in Santa ... findings on new lung-sparing therapies for MPM, a rare ... and commonly affects the pleura, the lining of the ... Heart, Lung and Blood Institute, the 3rd Annual International ...
(Date:5/24/2013)...  Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ) ... Deutsche Bank Health Care Conference to be held May ... Adrian Adams , Chief Executive Officer and ... Company and its product pipeline at 12:00 p.m. ET ... http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The presentation will also ...
(Date:5/24/2013)... , May 24, 2013 The ... for systemic delivery of therapeutic agents has been receiving ... drug delivery showing significant promise. The crucial formulation considerations ... delivery device play a major role in the efficiency ... in the development of new formulation techniques and devices ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2
... 9, 2008 /PRNewswire-FirstCall/ - Echo,Therapeutics (OTC Bulletin ... human feasibility study of the Prelude(TM) SkinPrep ... for its,Symphony(TM) tCGM System, a novel transdermal ... diabetes home use and hospital critical,care markets. ...
... The Association,for Professionals in Infection Control and Epidemiology ... of Albany, NY, has been named,the 2008 recipient ... the annual award to an infection prevention and ... DeMille, a pioneer,in infection control. The award will ...
Cached Medicine Technology:Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 2Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 3Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 4Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System 5New York Infection Prevention Expert Named Recipient of Carole DeMille Award 2
(Date:5/24/2013)... With Memorial Day Weekend upon us, cookout season has officially ... to help prevent grill fires throughout the spring and summer. ... that gas grills led to an average of 7,100 home ... meanwhile, caused approximately 1,200 home fires per year during that ... the following tips from the NFPA to help protect your ...
(Date:5/24/2013)... E-Dentists.com has announced the launch of ... Media Surge, a leading medical Internet marketing agency. ... service will focus on providing dentists the help they ... their competitive keywords. The dental SEO analysis covers a ... on what their competitors are doing right. The goal ...
(Date:5/24/2013)... Drugs commonly used to treat glaucoma may cause droopy ... vision, according to a new study. The drugs, ... reduce eye pressure, have already been shown to cause ... researchers said, suggesting that the new findings could lead ... be conservative when prescribing these drugs, the researchers added, ...
(Date:5/24/2013)... researchers failed to replicate what appeared to be breakthrough ... they were published last year in the journal ... 2012, suggested that the drug bexarotene (marketed as Targretin) ... (Aβ) a pathological hallmark of Alzheimer,s disease ... of the 2012 report, drug treatment quickly removed most ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 The nation’s ... involving Intuitive Surgical Inc.’s da Vinci Surgical System concluded ... records, a Washington State Court jury ruled in a ... training a surgeon who performed a da Vinci prostatectomy ... The patient’s family had alleged in their lawsuit that ...
Breaking Medicine News(10 mins):Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3
... can detect non-small cell lung cancer (NSCLC) in very early ... test is highly accurate// and has successfully detected cancer nodules ... ,The University has now decided to partner with ... detect lung cancer in smokers as well as in other ...
... Australia’s Townsville will be revolutionized after a A$ 3 million ... (JCU).// A rural medical school has also been announced by ... clinic will cost A$ 3 million, and permit students to ... give them experience with regard medicine in remote and rural ...
... and Technology Committee has issued a warning that if a ... a severe shortage of food. // ,The ... on an international level and has asked the Government to ... arise. As staff continue to take leave and supermarket deliveries ...
... to Food science and consumer acceptance in Norway the ... do experts to cheese.// ,The food compared was ... expert dairy assessors. The rating was based on reaction ... was difference of opinion in both factions. As a ...
... well known how nutritional dense milk is so ... to develop valuable new products with nutraceutical, pharmaceutical ... initiated in The University of Queensland's Institute for ... company. Microbial Screening Technologies (MST) has teamed up ...
... from the Pennsylvania State University are trying to determine why ... zebra fish. The team led by Mark Shriver studied genes ... in their key gene plays a major role in determining ... Science, may not only help explain why people of European ...
Cached Medicine News:
... manual hemostasis analyzer that is ideal ... PTs, aPTTs, thrombins, fibrinogens and factor ... testing, this analyzer is small in ... time and labor saving benefits. Operation ...
... The STart benchtop coagulation ... of electro-mechanical clot detection. This ... icteric or other optically dense ... offers programmable and preprogrammed assays ...
... STA-R Evolution is a fully-automated, stand-alone ... total laboratory automation line. Clotting, chromogenic ... in random access mode. The system's ... high throughput and rapid processing of ...
The ACL 9000 together with an extensive test menu and superior technology is backed by high-quality service to keep the lab running efficiently....
Medicine Products: